FAST technology
In response to the need to reduce discovery timelines and increase the rate at which new chemical entities are brought to market, SGX (Structural GenomiX) has developed a novel technology called FAST (Fragments of Active Structures) to serve as an engine for high-quality lead generation.
In response to the need to reduce discovery timelines and increase the rate at which new chemical entities are brought to market, SGX (Structural GenomiX) has developed a novel technology called FAST (Fragments of Active Structures) to serve as an engine for high-quality lead generation.
The technology combines the power of x-ray crystallography with the strengths of combinatorial chemistry, in a novel high-throughput screening approach.
SGX has announced its pipeline of early stage drug candidates for leukaemia, inflammation, and urological cancer.
These are:
• developed an inhibitor targeting a Bcr-Abl mutant (T315I) that is resistant to Gleevec, the only available therapy for chronic myelogenous leukaemia. It is projected to file an IND by 2005.
• jointly developing novel urological cancer kinase targets with UroGene (France). SGX and UroGene project to file an IND by end of 2005 for superficial bladder cancer.
SGX industry-leading structure determination capabilities led to 'first to structure' for multiple high profile medical targets, such as SARS virus prote-ase, CFTR NBD1 for cystic fibrosis, and Bcr-Abl (T315I).